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1. Introduction 
Gene therapy relies on the delivery of therapeutic genes into patients’ cells. The micro-
devices used to reach the cells and to transfer the gene payload are called gene vectors. Viral 
packaging machinery is often utilized to generate the particles transporting the cargo genes. 
Lentiviruses, a subgroup of retroviruses, are highly suitable for remodeling into gene 
transfer vectors because they offer the stability of transgene expression, the ability to reach 
the nuclei of the therapeutically important non-dividing cells and are known to have a low 
immunogenic profile. Well studied members of the lentiviruses include human 
immunodeficiency viruses 1 and 2 (HIV-1 and HIV-2), feline immunodeficiency virus (FIV) 
and equine infectious anemia virus (EIAV). 
It is important not to confuse “gene delivery vectors” and “gene cloning vectors”. While the 
former are microparticles delivering genes, the latter are replicating vehicles for the 
amplification of nucleic acid sequences. “Gene delivery vectors” and “gene cloning vectors” 
coincide when the naked DNA of replicating bacterial plasmids or replication competent 
viruses is used for gene delivery into cells. Viral gene delivery vectors are normally non-
replicating and should correctly be referred to as “viral vectors”, not “viruses”. Particles of 
viral vectors can be referred to as “virions” or “transducing particles”, because viral gene 
transfer is traditionally described as “transduction”.  Replication deficient viral gene vector 
particles are similar to “defective interfering particles”, that is, faulty non-self-viable virions 
arising during natural viral infections and competing with non-defective virions, which 
were described in virology literature many years ago.  
Native lentiviral envelope proteins, which determine the cell range of viral infectivity 
(tropism) and mediate the fusion of viral and cellular membranes, are always composed 
from two non-covalently attached subunits, one of which (e.g. gp41 glycoprotein in HIV-1) 
is membrane-embedded and the other is an external subunit (e.g. gp120 glycoprotein in 
HIV-1).  This arrangement makes lentiviruses notoriously unstable because of their 
tendency to shed the external subunit of the envelope protein. As the virion’s stability is a 
pre-requisite for the effective purification and concentration of viral vector preparations, in 
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lentiviral gene vectors native lentiviral envelope proteins are routinely replaced with stable 
heterologous viral envelope glycoproteins, most commonly G-protein of Vesicular 
Stomatitis Virus (VSV) or, alternatively, G protein of Rabies Virus. Both VSV and Rabies 
Virus belong to the family of rhabdoviruses. VSV-G protein has a broad tropism towards 
lipid membranes while rabies G has a distinct tropism to neural cells. The interchangeable 
use of envelope proteins by viruses belonging to different groups is very common and is 
called “pseudotyping”. Lentiviral vectors can be pseudotyped with many other proteins, 
including artificially designed proteins, in order to improve infectivity for a particular cell 
type or, alternatively, to restrict the viral tropism. The rules of efficient pseudotyping are not 
yet completely clear, but one of the obvious requirements is the ability of the “cytoplasmic 
tails” of the membrane-embedded putative envelope proteins to fit into the available space 
between the viral capsid and the lipid envelope of the virion. Sometimes lentiviral vectors 
are pseudotyped by a cocktail of various viral, cellular or artificial membrane proteins. The 
structure of the lentiviral gene vector virion is presented in Figure 1. 
 
 
Fig. 1. A typical lentiviral vector particle 
Lentiviral vectors are a promising tool for both in vivo and ex vivo gene therapy 
(Srinivasakumar 2001; Maier, von Kalle et al. 2010). These vectors can be used for 
therapeutic strategies relying on both transgene expression and gene correction (Al-Allaf, 
Coutelle et al. 2010). In addition, lentiviral gene vectors are extensively used in basic 
biomedical research to deliver genes for the expression of proteins and RNAs, e.g. shRNAs 
for gene knockdown. Lentiviral gene vectors are also being investigated as vaccines for 
immunization.  
In some situations the use of classical lentiviral vectors can be compounded by the following 
problems: 1) insertional mutagenesis with a potential for malignant transformation; 2) 
relative difficulty of obtaining high titre concentrated viral vector preparations and the 
related problem of transduction inhibitors in the viral preparations; 3) toxicity of the 
commonly used VSV-G envelope protein at high multiplicity of infection; 4) limited insert 
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capacity because of the RNA size packaging constraints specified by the lentiviral Gag 
complex.  
Some of the above problems can be overcome. For example, contamination of lentiviral 
vector preparations with some inhibitors of infection can be avoided by the viral 
preparation concentration and purification by chromatography methods, which can be 
sufficiently gentle in comparison to ultracentrifugation based methods, which often result in 
a substantial fraction of the viral vector particles becoming inactivated. The reduction of  
viral vector losses during concentration is important, in particular because defective virions 
can compete with the functional virions and inhibit transduction  (Geraerts, Willems et al. 
2006). Perhaps the most dramatic improvement of the lentiviral vectors was the introduction 
of non-integrating lentiviral vectors, which do not cause genomic mutations arising via the 
random genomic integration of the classical lentiviral vectors (Section 5 of this review). 
Lentiviral vectors can be assembled through transient co-transfection of the lentiviral vector 
backbone plasmid with helper plasmids expressing viral packaging functions or by stably 
transfected packaging cell lines. The first production method is currently a preferred choice 
because of its greater flexibility. A small undesirable possibility of reconstitution of the 
replication competent virus in the cells used for the lentiviral vector packaging can 
compromise safety. So, the chances of formation of a complete viral genome are customarily 
reduced by splitting genes for helper packaging functions between separate plasmids. For 
example, a common three-plasmid transient co-transfection packaging system employs a 
helper plasmid with genes for the structural Gag polyprotein, the catalytic GagPol 
polyprotein and the accessory HIV-1 Rev and Tat proteins (e.g. psPAX2) plus a helper 
plasmid for an envelope protein (e.g. VSV-G plasmid pMD2G). In a four-plasmid packaging 
system the genes for the Gag and GagPol functions on the one hand and the Rev function on 
the other hand are split between two different helper plasmids (with the Tat function 
missing altogether). Universally used cell lines for the packaging of lentiviral vectors in 
transient co-transfection are HEK293 cell line and its derivatives. HEK293 cells were 
produced by selecting an individual immortalised clone among a mixed population of 
human embryonic kidney cells transformed with DNA fragments of adenovirus type 5. 
HEK293 cells can be efficiently transfected by the calcium phosphate method, protocols 
involving cationic lipids (e.g. Fugene 6 and Fugene HD) or electroporation. Contamination 
of plasmid DNA with co-purifying bacterial lypopolysaccharides should be avoided, as 
these endotoxins can substantially reduce the efficiency of transfection. HEK293T cells, 
which were derived from HEK293 cells and stably express large Simian Virus 40 (SV40) 
large T-antigen, are purported to generate retroviral and lentiviral vector preparations with 
particularly high titres. Thus, at present HEK293T and closely related HEK293FT cells are 
predominantly used for lentiviral vector production via transient co-transfection of the 
backbone vector plasmid and the helper plasmids. The abundance of lentiviral vector 
genomic RNA and levels of expression of VSV-G protein, Gag and GagPol polyproteins plus 
the accessory protein Rev in the packaging cells are of paramount importance for the 
resultant lentiviral vector titre. The ratio of a lentiviral backbone vector plasmid DNA and 
non-vector helper packaging plasmids is used to regulate the relative amount of genomic 
RNA and packaging proteins. In part, the optimal balance depends on the known toxicity of 
the excess VSV-G protein to mammalian cells. Clontech-Takara and ThermoFisherScientific-
OpenBiosystems offer mixtures of plasmids with tetracycline-inducible expression of the 
trans-acting packaging functions. As an alternative to plasmids, adenoviral vectors (Kuate, 
Stefanou et al. 2004) or baculoviral vectors (Lesch, Laitinen et al. 2011) can be used to deliver 
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DNA cassettes for the transient expression of lentiviral packaging proteins and the lentiviral 
vector backbone modules. Clearly, this method can broaden the range of cell lines suitable 
for lentiviral packaging, as receptors for adenoviruses are commonly expressed by different 
types of cells.  
The process of cell transduction by a viral vector follows the infection pathway of the 
cognate virus. There are several parameters characterizing the transduction of cells with a 
viral vector. Firstly, efficiency of transduction, defined as percentage of transduced cells out 
of all cells treated with a viral vector preparation, is a common and readily-obtained read-
out quantity in transduction experiments. The second commonly used parameter is end-
point titre, which is the number of “transduction units” per volume of the viral vector 
preparation with the number of transduced cells (corresponding to the “transduction units”) 
estimated when one of the highest dilutions of the viral preparation is used to infect the 
cells. The third important parameter describing transduction by a viral vector is the 
multiplicity of infection, that is, the average number of functional transducing particles 
infecting one cell. The infection of a cell by a lentiviral vector normally results in the 
establishment of one or several copies of the corresponding provirus. The efficiency of the 
transduction of the cell population by a retroviral vector, which is a function of the 
multiplicity of infection, correlates with a number of proviruses in the genome of the 
infected cell (Kustikova, Wahlers et al. 2003). Thus, the obtained transgene copy number 
reflects the multiplicity of infection. Expression of retroviral envelope proteins is known to 
block superinfection (i.e. extra-infection by the same virus) of the infected cells through the 
depletion of the cognate cellular receptor molecules during their intracellular transport. This 
mechanism, though, does not apply to VSV-G protein pseudotyped lentiviral vectors, which 
neither have protein cellular receptors, nor code for an envelope protein under typical 
circumstances. Therefore, it is possible to increase the number of the lentiviral vector 
proviruses and, hence, transgene copy number by repeated rounds of superinfection.  
As an alternative to gene delivery with packaged lentiviral vectors, the cargo genes within 
lentiviral vector DNA sequences can be transferred in situ “on the back” of other viral gene 
vectors, such as adenoviral or herpes virus based vectors. These, “dual-viral systems”, e.g. 
adenovirus-retrovirus hybrid vectors, can deliver attenuated lentiviral vectors competent for 
replication and packaging in order to achieve “a booster effect” due to lentiviral vector 
spread in situ (Dalba, Bellier et al. 2007). In addition, such delivery systems allow for the 
exploitation of the cellular tropism of some well-established non-lentiviral vectors, 
particularly vectors based on non-enveloped viruses which lack membrane-imbedded anti-
receptors suitable for pseudotyping (Soifer, Higo et al. 2002).  
The stable maintenance of lentiviral vectors makes them a highly suitable tool for various 
cell-fate mapping studies and also as sensors of cell differentiation. Tracing cells with a 
specific differentiation status is important in biomedical research, e.g. in stem cell studies 
(Gallo, Grimaldi et al. 2008). The packaging size constraints make it a challenge to avoid 
cross-talk between various elements within lentiviral vectors and, therefore, require the 
thoughtful design of lentiviral vectors with tissue specific transgene expression (Hager, 
Frame et al. 2008).  
2. Elements of lentiviral vector backbone plasmids 
The lentiviral vector genome has the size of about 10 kb and can be conveniently amplified 
by cloning its complete or partial DNA copy in the bacterial plasmid cloning vectors. Such 
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lentiviral vector  backbone plasmids are similar to other vector plasmids for mammalian 
gene expression, which were recently reviewed (Tolmachov 2009). The immediate purpose 
of the lentiviral vector backbone plasmid is to serve as a template for the transcription 
generating viral vector genomic RNA, which can be packaged into the lentiviral vector 
particles. The bacterial portion of the vector plasmid is not transcribed and, therefore, is not 
included in the genomic RNA of the viral vector. Thus, a typical lentiviral vector backbone 
plasmid consists of a bacterial plasmid portion, lentiviral elements required for viral vector 
RNA packaging and intracellular transport, a marker gene and/or a cargo gene and 
elements for their regulation, optional chromatin-control elements and sites for convenient 
plasmid DNA re-engineering (Figure 2). 
 
 
CMVp – the immediate early CMV promoter; delta 5’-LTR and delta 3’-LTR – the long terminal repeats 
with some deletions; Psi & RRE – the packaging sequence ψ and the Rev Response Element (RRE); 
PGKp – the mouse phosphoglycerol kinase promoter; EGFP-NLS – the gene for nuclear targeted 
enhanced GFP protein; ori-pMB1 – the multicopy origin of replication originating from the wild type 
plasmid pMB1; Ap-R – the ampicillin resistance marker, the gene for β-lactamase. 
Fig. 2. A typical lentiviral vector backbone plasmid 
Evolution has shaped both bacterial plasmid and viral genomes as mosaic assemblies, which 
can be disassembled into individual functional units that can then be assembled back into new 
chimeras. Thus, the genomes of lentiviral vectors consist of a number of genetic elements, of 
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which lentiviral elements per se are only a fraction (often less than 30% of the vector genome). 
Lentiviral sequences essential for lentiviral gene vectors are Long Terminal Repeats (LTRs, 
which can be complete or partially deleted) for proviral integration and the packaging ψ 
sequence within the genome region proximal to the 5’-LTR. A viral life cycle involving tight 
nucleic acid packaging into protein shells (capsids) requires compactness from the viral genetic 
elements. Thus, terse genetic elements from various unrelated viruses are particularly suitable 
for employment within lentiviral vector constructs. Various cargo genes can be delivered with 
lentiviral vectors. Because of the lentiviral packaging size constraints, the shorter, cDNA-
based, versions of the genes are normally preferable. As the space within the lentiviral capsid 
is limited, one would only include an intron within a lentiviral vector born cargo gene if it 
provides an important regulatory function for the gene’s expression.  
Other regulatory genetic elements within lentiviral vectors include viral or cellular 
promoters and enhancers, splicing control elements if an intron is included, RNA stabilizing 
components like Woodchuck hepatitis virus Post-transcriptional Regulatory Element 
(WPRE) and, with a pinch of salt, polyadenylation signals (see discussion in Section 2.4). 
Thus, the lentiviral vector backbone plasmid normally includes a bacterial plasmid segment, 
cis-elements of the lentiviral packaging machinery and an elective strong promoter to drive 
the synthesis of lentiviral vector’s genomic RNA, cargo genes (e.g. marker genes, 
therapeutic genes) and genetic elements for their control. Optionally, lentiviral vector 
backbone plasmids can also contain sites for efficient transport of vector RNA from nucleus, 
for episomal maintenance of proviruses, site-specific genomic integration and also sites 
alleviating plasmid manipulation, e.g. polylinkers with restriction enzyme recognition sites. 
2.1 Bacterial plasmid segment  
Lentiviral vector backbone plasmids are propagated in bacteria and hence need to contain a 
bacterial origin of replication to drive the DNA amplification.  Plasmid origins of replication 
are traditionally classified into a “stringent control of the plasmid copy number” group and 
a “relaxed control of the plasmid copy number” group. High number of plasmid copies per 
cell, which is typical for the “relaxed control” group, insures the high yield of the plasmid 
DNA. However a high plasmid copy number can place substantial stress onto the host cells, 
thereby decreasing their growth rate and, thus, resulting in occasional accumulation of cells 
with the shortened, “deletion”, plasmid mutants or cells lacking the plasmid altogether.  In 
contrast, replicons from a “stringent control” group have a lower number of plasmid copies 
per cell and hence comparatively small plasmid DNA yields, however plasmids driven by 
these replicons only rarely place a selective disadvantage onto their host cells. In addition, 
stable maintenance of the stringent control replicons is insured by their “partition” 
functions, which are responsible for the faithful distribution of plasmids between daughter 
cells after cell divisions. Classic relaxed control replicons are derived from plasmids ColE1 
and pMB1, while typical stringent control replicons originate from plasmids RSF1010, 
pSC101, F-factor, and bacteriophage P1.  A particularly convenient replication system, 
which is used in the lentiviral vector backbone plasmids, is borrowed from the plasmid R6K. 
This plasmid has several origins of replication, all dependent on the Π-protein encoded by 
the plasmid’s pir gene. Thus, a lentiviral backbone plasmid with R6Kγ replicon can replicate 
only in the bacterial strains expressing the Π-protein. The copy number of ori-R6Kγ-driven 
plasmids can be increased substantially if the plasmid is transferred to an array of strains 
expressing various “copy-up” mutant versions of the Π-protein, thus giving the flexibility to 
choose the optimal copy number for a particular lentiviral backbone plasmid. 
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To select bacterial tranformants during plasmid modifications and to prevent plasmid loss 
using selective pressure for plasmid-containing cells, the bacterial plasmid segment should 
include a suitable selection marker. The standard solution is to employ an antibiotic 
selection gene such as the ampicillin resistance gene for β-lactamase or the chloramphenicol 
resistance gene for chloramphenicol acetyl transferase. Large scale preparations of plasmid 
DNA with antibiotic resistance genes might lead to the undesirable escape of these genes 
into environment. Thus, genetic systems, which rely on a short RNA-expressing gene as a 
plasmid selection marker, can be contrived (Luke, Carnes et al. 2009).  
Regrettably, it is relatively common for lentiviral vector backbone plasmids to suffer from 
structural and maintenance instability in bacteria. There are several common factors 
contributing to this instability. Lentiviral vector backbone plasmids are necessarily greater 
than 9 kb in size; if their replication is driven by a replication origin with “relaxed 
control” of the plasmid copy number, spontaneously arising deletion mutants have a 
propensity to replicate faster and, as a result, tend to establish dominance in the mixed 
plasmid population. Plasmid deletions can occur through homologous or illegitimate 
recombination between inverted repeats of the lentiviral LTRs. A mosaic of eukaryotic 
sequences within the lentiviral vector backbone plasmid might contain cryptic bacterial 
promoters, which could be able to drive the expression of toxic RNAs and polypeptides 
creating a negative selection pressure on the population of bacterial cells harbouring the 
desired plasmids. It should be noted that the ampicillin resistance gene coding for β-
lactamase, which is often used in the commercially available lentiviral backbone plasmids 
as a selection marker, is poorly suited for long-term bacterial selection in liquid cultures. 
This is because wild type β-lactamase is secreted in Escherichia coli and can destroy 
ampicillin before the bacterial culture is fully grown. Thus, if a particular lentiviral 
backbone plasmid would have a maintenance problem, the overgrowth of plasmidless 
cells in liquid culture would not be stopped by ampicillin. In such a situation, the use of 
alternative non-ampicillin-based selection marker is recommended. Alternatively, as 
much bacterial cultivation as possible should be performed on a solid agar medium 
containing ampicillin, where the spread of ampicillin-destroying β-lactamase is slower. 
For example, a seeding stock for a liquid plasmid maxi-preparation culture can be grown 
from an individual colony on agar plates with ampicillin instead of a liquid overnight 
culture. Non-secreted, cytosolic, mutant versions of β-lactamase were described and can 
be used for efficient selection of bacteria harbouring maintenance-compromised lentiviral 
vector backbone plasmids.  
2.2 Cis-acting elements of the lentiviral molecular machinery 
The standard purpose of lentiviral vector backbone plasmids is to provide a template for the 
synthesis of lentiviral vector genomic RNA, which can be successfully packaged into lentiviral 
vector virions, reverse transcribed and integrated within the cellular genome. The Ψ-sequence 
close to the 5’-LTR is strictly required for the packaging of RNA by the Gag polyprotein. A 
substantial portion of the sequences within the LTRs of the lentiviral genome is required for 
chromosomal integration. However, some sequences within the LTRs can be removed without 
reduction in the integration efficiency. Wild-type retroviral and lentiviral genomes contain a 
promoter within their 5’-LTR to drive expression of genomic RNA. The promoter sequences 
can be deleted from the 5’-LTR DNA segment in the lentiviral vector backbone plasmids and a 
strong constitutive promoter capable of directing synthesis of the vector genomic RNA, e.g. 
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immediate early CMV promoter, can be placed externally to the bracket of the lentiviral 
sequences within the plasmids. As the accessory lentiviral protein Tat is required for the 
activation of the promoter within the wild type 5’-LTR of HIV-1, the use of an external 
promoter for genomic RNA synthesis allows exclusion of the Tat gene from the packaging 
system with the consequent reduction in the probability for the re-constitution of the 
replication competent virus and the corresponding improvement in safety (Dull, Zufferey et al. 
1998). A substantial fraction of the currently used lentiviral vectors are “self-inactivating” 
(SIN) due to a deletion within their 3’-LTR. Indeed, as the DNA-copy of the 5’-LTR of the 
vector provirus is always synthesized by reverse transcription from the template of the 3’-LTR, 
proviruses of the SIN vectors lack sequences required for the re-constitution of the lentiviral 
promoter within the 5’-LTR segment of the vector provirus and the synthesis of the lentiviral 
vector genomic RNA from the provirus template. Thus, the SIN-vectors cannot be re-
distributed from the target cells, which is beneficial for their safety profile.  
Lentiviruses possess molecular machinery to enter into the nuclei of postmitotic, non-
dividing cells with an intact nuclear envelope. Lentiviral nuclear-penetration apparatus is in 
part dependent on the triple-stranded structure created during reverse transcription of the 
lentiviral genomic RNA, “the central DNA flap” (Riviere, Darlix et al. 2010). Central 
Polypurine Tract (cPPT) and Central Termination Sequence (CTS) are required for the 
formation of “the flap”. Therefore, DNA sequences for cPPT and CTS need to be present in 
the plasmid template of the nuclear penetrating lentiviral vectors. 
Rev protein of HIV-1 is known to increase lentiviral vector titres by promoting the export of 
genomic RNA from the nucleus. This export depends on the Rev Response Element (RRE) 
sequence within genomic RNA. Therefore, the RRE sequence is a desirable building block 
for inclusion into the lentiviral vector backbone plasmids. 
2.3 Marker genes for mammalian cells 
The concentration of lentiviral vector particles can be assessed by their ability to transduce 
cells and by physical measurements estimating the number of virions in a volume. A 
substantial number of virions in lentiviral preparations can be infection defective, so 
transduction data are vital for the evaluation of the titre of functional lentiviral vector particles. 
Convenient markers for the assessment of efficiency of transduction and for the fate mapping of 
transduced cells include genes for fluorescent proteins, drug resistance proteins, luciferase and 
cell surface antigens. More practical markers are easily detected in live cells, while others 
require fixation of the live material. Enzyme coding genes, such as the lacZ gene for bacterial β-
galactosidase, can be used as transduction markers, but lost some of their initial popularity 
because of the need to fix and, thus, to kill the transduced cells before colour reaction with 
enzymatic substrates. In addition, the lacZ gene is large (3075 bp), and occupies a substantial 
portion of the permissible payload size within lentiviral vectors. Similarly, detection of 
intracellular proteins by immunostaining requires cells to be killed by permeabilization of their 
membranes and fixation. Thoughtful choice of the viral vector marker is important for the 
straightforward collection of data and their faithful interpretation. Most marker proteins are 
small and do not illicit a substantial immune reaction in vivo. It is important to plan a 
convenient intracellular localization of the marker proteins as this can affect their activity and 
can minimize background signal. Genetic determinants used to direct proteins to a specific 
subcellular compartment include nuclear localization signals (NLS), chromosome binding 
moieties (e.g. histon H2B) and domains for plasma membrane association, endoplasmic 
 
Designing Lentiviral Gene Vectors 
 
271 
reticulum retention, targeting to mitochondria, peroxisomes, Golgi-apparatus, actin filaments 
and microtubules. Fused signal sequences or protein domains must not interfere with the 
marker protein multimer formation if the quaternal protein structure is required for its activity. 
Drug resistance (normally antibiotic resistance) genes are especially suitable for tasks 
requiring the establishment of stably transduced cell clones originating from individual 
transduced cells. The choice of a particular drug resistance gene can be affected by its size. 
The gene for blasticidin resistance, bsr, is 423 bp long and is particularly compact. In 
contrast, the gene for hygromycin resistance is 1038 bp long, and, therefore, is a less 
attractive choice if the available space within the lentiviral vector is limited. Different drugs 
cause cell death with dissimilar rates and their minimal inhibitory concentrations vary for 
different types of cells. The number of surviving transduced cell clones is typically higher at 
lower drug concentrations. Other frequently used antibiotic resistance markers include 
genes for resistance to zeocin, puromycin and neomycin analogue G418. Drug sensitivity 
genes, such as HSV thymidine kinase (TK), can also be delivered by lentiviral vectors. These 
genes are highly instrumental for cell suicide systems in cancer gene therapy, but are 
difficult to use as transduction markers.  
Fluorescent proteins are remarkably convenient as gene transfer markers because they can 
be detected both in live and fixed cells. The largest family of fluorescent proteins originates 
from the green fluorescent protein (GFP) of jellyfish Aequoria victoria.  Systematic protein 
engineering efforts produced mutant derivatives of GFP with increased brightness and 
widely different excitation and emission spectra (e.g. blue, cyan and yellow fluorescent 
proteins). Similarly, dsRed protein of coral Discosoma sp. was used to create a family of 
proteins including the orange fluorescent protein mOrange and the far-red fluorescent 
protein E2-Crimson. A number of specialized versions of fluorescent proteins were 
obtained, e.g. reduced half-life GFP for the collection of dynamic gene expression data. 
Fluorescently activated cell sorting (FACS) is the method of choice both for analytical 
analysis of the transduced fluorescent cells and for their preparative isolation. Fluorescence-
based microscopy is another convenient and informative method; however, 3-D imaging of 
fluorescent material is complicated by the extinction of both excitation and emission light in 
the thick slices. Still, the image data collected from thin slices can be assembled into 3-D 
images using computational algorithms. Computational algorithms can be also applied for 
“image de-convolution” in order to achieve some improvement of image quality using 
fluorescence data obtained directly on the thick specimens. 
The titre of a lentiviral vector depend to a large degree on the type of the marker used for 
analysis. Indeed, the titre determined by detecting the fluorescent transduction markers is 
usually higher than the titre obtained by counting drug resistant cell clones.  
Genes for luminescence proteins can be transferred by lentiviral vectors and used as cell 
tracers (Reumers, Deroose et al. 2008). Luciferases from North American firefly Photinus 
pyralis and sea pansy Renilla reniformis are commonly used. The two luciferases use different 
substrates for light production, this can be exploited to create internal control for 
luminescence in “dual luciferase reporter assays” used, e.g., for promoter strength testing or 
shRNA/siRNA analysis. The “baseline” luciferase marker (normally Renilla luciferase) can 
be delivered for expression on a separate vector or on the same vector. A version of firefly 
luciferase with enhanced expression in mammalian cells (luc2) was developed by Promega 
by codon optimization (as discussed in Section 2.4) and elimination of predicted 
transcription factor binding sites within the reporter gene sequence. On the basis of luc2, 
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Promega developed luciferases with a higher rate of degradation such as luc2P (containing 
PEST protein degradation signal (“degron”) on the C-terminus or luc2CP (containing CL1 
and PEST protein degrons on the C-terminus). PEST is a 40 amino acid sequence present in 
the C-terminal region of mouse ornithine decarboxylase. CL1 is a 16 amino acid degron 
from yeast. This signal was also optimized for expression in mammalian cells. Versions of 
luciferase with the degradation signals improve responsiveness to factors enhancing or 
inhibiting luciferase expression. Other specialized versions of luciferases are available. For 
example, secreted firefly luciferase is convenient to measure the luciferase activity of live 
cells in tissue culture. Renilla luciferase-neoR fusion protein was generated and can be used 
for both cell clone selection and as an internal luminescence control. In vivo “whole animal” 
detection of luminescence is a common approach with no excitation light being required and 
with the efficient amplification of emitted photons. However, low spatial resolution limits 
due to light dispersion in the animal restrict the expediency of this approach. 
Surface antigen markers, e.g. extracellular domain of CD4, truncated low-affinity nerve 
growth factor (LNGFR) or truncated mouse MHC class I molecule H-2Kk can be used as cell 
markers for antibody-mediated conjugation with paramagnetic particles, which can be used 
for both magnetic cell sorting and magnetic resonance imaging (So, Hotee et al. 2005). The 
intracellular domains of these proteins are removed to avoid signal transduction and the 
extracellular domains are supplied with GPI-lipidation signal for plasma-membrane 
anchoring (as in Miltenyi Biotec MAC SelectTM system). Background signal during whole-
animal imaging can be avoided by using species-specific monoclonal antibodies for the cell 
surface marker proteins in a heterologous host organism. 
2.4 Genetic elements for controlling the expression of marker genes and cargo genes 
in lentiviral vectors 
In general, cis-acting elements strictly required for gene expression in eukaryotes are a 
minimal promoter and a transcription terminator. Genes coding for proteins (cistrons) also 
necessarily contain: 1) the translation start codon ATG with the surrounding Kozak consensus 
sequence controlling translation initiation; 2) the protein coding sequence; 3) the stop codon.  
Protein-encoding genes are transcribed by eukaryotic Polymerase II from Polymerase II 
specific promoters. The sequence of the Polymerase II promoters is variable; however, “TATA-
box” with the consensus sequence 5’-TATAAAA-3’ is normally found 20-25 bp upstream of 
the transcription start site. In addition, minimal Polymerase II promoters often contain “CAT-
box” with the consensus sequence 5’-GGCCAATCT-3’ at the position -70 relative to the 
transcription start site. The Kozak consensus sequence is important for expression of protein-
coding transgenes born on lentiviral vectors. The DNA template for one of the strong versions 
of the Kozak sequence can be written down as 5’-gccaccATGgcg-3’. 
The Polymerase II transcripts, e.g. mRNAs, are nearly always modified by the addition of 7-
methylguanosine (the “cap”) to their 5’-ends and the addition of the homopolymeric tail of 
adenosine nucleotides to their 3’-ends. Polyadenylation of eukaryotic mRNAs is important 
for their protection from exonucleolytic attack and for their export out of nucleus. It also 
serves as a means of transcription termination. For mRNA to be polyadenylated, it should 
contain a specific signal sequence downstream of its polypeptide coding sequence. In 
general, a DNA sequence for the functional “polyadenylation signal” (pA signal), which is 
suitable for insertion into lentiviral vector backbone plasmids, is several hundred 
nucleotides long and is borrowed from a mammalian gene or a viral genome. Commonly 
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used pA signal sites are taken from the rabbit β-globin gene, human growth hormone gene 
and human herpes virus (HSV) thymidine kinase (TK) gene. The sequence 5’-AAUAAA-3’ 
located 10-30 nucleotides upstream of the cleavage site is highly conserved but is not strictly 
required for the polyadenylation of mammalian mRNAs. A very important feature of the 
lentiviral vector backbone is the pA signal in its 3’-LTR. This signal functions as a terminator 
for wild type lentiviral RNAs including complete lentiviral genomic RNA. As the 3’-LTR 
sequence itself is strictly required for chromosomal integration in lentiviruses, any foreign 
pA signals which can cause premature termination of the genomic RNA are bound to 
reduce the amount of transductionally active genomic RNA, and, therefore, to diminish 
drastically the titre of the functional lentiviral vector particles (Hager, Frame et al. 2008). 
Thus, foreign pA signals within lentiviral vectors should be either avoided altogether, or 
weakened, or positioned to terminate the transcription of the anti-genomic DNA strand 
only. With this challenge in view, it should be noted that while most pA signal sites act 
unidirectionally, a pA signal borrowed from SV40 viral genome is known to terminate RNA 
and to promote polyadenylation irrespective of transcription direction. A brief look at the 
transcription map of SV40 can explain this fluke. Indeed, two opposing transcription waves 
of SV40 meet and terminate at its polyadenylation signal site, which is, therefore, an overlap 
of two opposing polyadenylation signals. 
Natural Polymerase II promoters are nearly always supplemented with one or several 
“enhancers”, that is, genetic elements, which up-regulate the activity of the promoter 
through binding to specific nuclear proteins, so-called “transcription factors”. Size 
limitations of the lentiviral payload and insufficiently precise enhancer localization data 
restrict the use of enhancers in the lentiviral vectors. However, small enhancer elements can 
still be used where, for example, tissue-specific or inducible transgene expression is desired.  
A typical eukaryotic protein-coding gene is a patchwork of coding exons and non-coding 
introns, so that the translation-grade mRNA is produced by the splicing of the primary     
transcript. The result of the splicing is the establishment of the phosphodiester bond 
between the AG dinucleotide at the 3’-end of the preceding exon and the G nucleotide at the 
5’-end of the subsequent exon within the transcript (Hiller and Platzer 2008). The interlacing 
sequences, the introns, are flanked with a “splice-donor” consensus sequence 5’-GTRAGT-3’ 
at their 5’-ends and a “splice-acceptor” sequence 5-YAG-3’ at their 3’-ends (where R is A or 
G, Y is C or T). In addition, introns contain a “branch point” 5’-YTRAY-3’ and a 
polypyrimidine tract, which are functionally important for successful splicing. As the 
payload space within the lentiviral vectors is limited, the standard practice is to include the 
genes in their complementary DNA (cDNA) form, that is, as spliced versions without 
introns. The introns, however, are not entirely inert genetically and occasionally take part in 
the regulation of gene expression. In such situations, the inclusion of small regulatory 
introns within lentiviral vectors can be considered (Le Hir, Nott et al. 2003).  
Coding sequences delivered by lentiviral vectors are often derived from non-mammalian 
organisms where the translation machinery is adapted to a non-mammalian profile of codon 
frequencies. Unusual codons, also called “hungry codons”, can cause undesirable pauses 
during translation and reduce the efficiency of gene expression. Therefore, the optimization 
of codon frequencies for the genes, which are born on the lentiviral vectors, is often 
advantageous. If the frequencies in a coding sequence are adapted to the human codon 
usage profile, the sequence is said to be “humanized” (Zeeberg 2002; Burgess-Brown, 
Sharma et al. 2008).  
  
Viral Gene Therapy 
 
274 
The stability of genomic RNA of lentiviral vectors is crucial for attaining high lentiviral 
vector titres and stability of the lentiviral vector encoded mRNAs is important for efficient 
transgene expression. It was discovered that an element from Woodchuck Hepatitis Virus 
(WHV) genome can operate at a post-transcriptional level to improve transgene expression. 
The sequence, called WHV Post-transcriptional Regulatory Element (WPRE) is thought to 
act by expediting the export of RNA from the nucleus with the concomitant reduction of the 
intra-nuclear RNA degradation. WPRE and a similar element from Human Hepatitis Virus 
(HBV) are extensively used in lentiviral vectors, where they are normally positioned 
immediately upstream from the 3’-LTR, primarily because of their vector titre enhancing 
properties. WPRE, as defined originally, was known to cause tumours in rodents, therefore, 
a safer version of WPRE with deleted sequences for the WHV X protein and its promoter 
was generated (Schambach, Bohne et al. 2006).  
Cistrons are not the only cargo genes delivered by the lentiviral vectors. Other payload 
genes include the genes for RNAi-exploiting “micro” RNAs (miRNAs) or their artificial 
analogues, “short hairpin” RNAs (shRNAs). These genes are transcribed by RNA 
Polymerases III or I from the corresponding promoters. The benefits of the lentiviral vectors, 
such as the relative stability of transgene expression and the ability to transduce postmitotic 
cells, considerably broaden the versatility of gene knock-down experiments with shRNAs 
(Rubinson, Dillon et al. 2003). A range of suitable lentiviral vectors, exploiting the high 
activity of hybrid miRNA-30-shRNA design, are offered by ThermoFisherScientific-
OpenBiosystems (Silva, Li et al. 2005).  
In summary, cis-acting elements regulating gene expression act in concert and in a cell-type-
specific manner. The inherent mosaicism of lentiviral genetic organization allows 
interchangeable use of an extensive array of genetic elements for the generation of new 
lentiviral vectors. However, some combinations of genetic determinants are less functional 
than others, so the optimization of the lentiviral vector set-up is usually required.  
2.5 Genetic elements for epigenetic maintenance of transgene expression 
It is a relatively common occurrence for transgene expression to die out both in terms of the 
reduction of the fraction of expressing cells and the decrease of the efficiency of expression. 
Integrated lentiviral proviruses are faithfully maintained in mammalian cells, so the reasons 
for the shutdown of transgene expression are mostly epigenetic. Malfunction of the 
transgene expression control elements is often blamed, indeed, the phenomenon is 
sometimes referred to as “promoter shut down”. Certainly, different promoters have 
various capabilities to maintain long-term transgene expression. In particular, some 
promoters tend to turn off in cell populations where they are not normally active. The 
shutdown of transgene expression is particularly common in cell populations undergoing 
differentiation (Bagchi, Kumar et al. 2006). Natural chromosomal integration of lentiviruses 
tends to occur in transcriptionally active areas of the genome where heterochromatin and 
DNA methylation are unlikely to interfere with transgene expression. However, as the cells 
differentiate, the pattern of heterochromatization and DNA methylation changes and some 
of the proviruses find themselves in the transcriptionally silent areas of the genome. 
There are many levels at which the longevity of transgene expression can be addressed 
through the lentiviral vector design, including: 1) control of the provirus amenity to 
methylation (e.g. purposeful exclusion of the methylation-prone CpG islands); 2) chromatin 
re-modeling control via cis-acting proviral elements; 3) choice of non-immunogenic 
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transgene products to prevent cell elimination via immune reaction in vivo; 4) choice of a 
suitable tissue-specific promoter-enhancer combination; 5) achieving the high copy number 
of proviruses; 6) control of the provirus integration sites via the preferences of the viral 
integrase or via harnessing the site-specific integration systems.  
In principle, the protection of proviruses from heterochromatin can be achieved with 
genomic insulators or other similar anti-heterochromatin elements. However, experiments 
with known insulators show that their effects on transgene expression from lentiviral 
proviruses are multi-vectorial depending on the cell context (Grandchamp, Henriot et al. 
2011). Ideally, targeting proviruses to a continuously active locus (e.g. human homologue of 
the mouse Rosa 26 locus) can resolve the transgene expression shutdown problem. An 
alternative solution is to escape chromatin-remodeling events by creating episomally 
maintained lentiviral proviruses (Section 5). 
2.6 Elements alleviating manipulation of lentiviral vector backbone plasmids 
The fairly large size of the lentiviral vector backbone plasmids means they contain a limited 
number of unique sites for restriction nucleases. Thus, it is often desirable to introduce 
artificial clusters of suitable unique restriction sites (polylinkers) to simplify the 
modification of these plasmids. Alternatively, selection schemes involving site-specific 
recombination can be used for repetitive modifications, e.g. for marker exchange or 
promoter exchange. In this scenario, the introduction of suitable site-specific recombination 
sites into the lentiviral vector backbone plasmid is required.  
As discussed in Section 2.1, lentiviral vector backbone plasmids are occasionally structurally 
unstable and/or poorly maintained. These plasmids are particularly vulnerable during 
initial establishment in bacteria. Instability of nascent recombinant plasmids can result in a 
practical unfeasibility of seemingly straightforward DNA cloning strategies. For example, 
the generation of new lentiviral vector backbone plasmids through inefficient ligation of two 
DNA fragments with blunt ends is normally very challenging. In such situations we 
recommend splitting the DNA cloning procedure into separate cloning steps, each one 
relying on either effective positive selection of new recombinant plasmids or on efficient 
ligation. For example, the insertion of additional DNA sequences into lentiviral vector 
backbone plasmids can take advantage of the “pop-in-pop-out” cloning strategy. In this 
approach, a plasmid containing the desired insert and marked with antibiotic resistance 
marker 1 is first fused with the lentiviral vector backbone plasmid marked with antibiotic 
resistance marker 2 using positive selection of the co-integrate plasmid with two antibiotics. 
The desired new lentiviral vector backbone plasmid is then obtained by removing the 
unwanted plasmid sequences from the resultant bi-replicon plasmid using restriction 
digestion and efficient intra-molecular ligation reaction. Clearly, this strategy for insertions 
into a lentiviral vector backbone plasmid requires the thoughtful placement of restriction 
sites conveniently accommodating both the “pop-in” step and the “pop-out” step. 
3. Engineering lentiviral vectors for the concomitant expression of several 
transgenes 
The genome sizes of non-defective wild type HIV-1 isolates are close to 9.5 kb. The lentiviral 
packaging size constraints are dictated by the geometry of the viral capsid and are thought 
to be fairly permissive of the smaller than wild type genome versions, but remarkably 
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intolerant of the larger than wild type variants. As lentiviral sequences required for genomic 
RNA packaging and chromosomal integration constitute about 2 kb, the available gene 
payload space within HIV-1 based lentiviral vectors should not be much more than 7.5 kb. 
Thus, the insert size capacity of the lentiviral vectors is completely appropriate for the vast 
majority of the monogenic applications but can present a challenge in situations where the 
delivery of several genes by a single vector is required. Therefore, various possible methods 
of gene cargo reduction have been explored.   
The expression of two or more cistrons from a single promoter can be achieved by the 
employment of internal ribosome entry site (IRES) elements, which are normally borrowed 
from viral genomes (Fux, Langer et al. 2004). The IRES sequences (about 0.5 kb) are inserted 
between the coding frames to facilitate translation of the downstream coding frames from 
the same transcript. IRES efficiency is not absolute and it is a common occurrence for the 
subsequent gene in the expression cassette to be expressed at a lower level than the 
preceding gene. As the length of the intercistronic inserts is an important factor in the IRES 
efficiency, the expression of the downstream genes can be improved by increasing or 
decreasing the sizes of the IRES inserts (Attal, Theron et al. 1999).  
Another common method used to compress the gene expression cassettes is to produce gene 
products as polyproteins, that is, large polypeptides, which are split into individual proteins 
by proteases recognizing the appropriate amino acid sequence cleavage motifs between the 
protein modules. In fact, lentiviruses use the same principle themselves as the Gag 
polyprotein is proteolytically processed inside the viral particles to form nucleocapsid, 
capsid, matrix proteins and the GagPol polyprotein is processed to form additionally viral 
protease, integrase and reverse transcriptase. The usual proteolytic signal, 2A, which is used 
in recombinant lentiviral gene vectors, is, however, borrowed not from lentiviruses but from 
the Foot-and-Mouth Disease Virus belonging to the family of picornaviruses. Multiple 
copies of the 2A sequence can be successfully used to indicate the desired break-up of the 
polyproteins. The method has its limitations as protein misfolding might occur, which 
would require some extra chaperone support.  
Quite often there is no need to separate several proteins as they can perform several 
functions remaining as a single polypeptide chain. In general, multifunctional fusion 
proteins are produced by the fusion of the coding sequences in the same translation frame. 
Some spacer peptides might be used to intercalate between the fused polypeptides to 
improve folding and to facilitate the functional activity of the individual protein domains. 
There are two common methods to achieve protein fusion: 1) the stop codon of the upstream 
coding unit is deleted and the start codon of the downstream coding unit is retained to 
obtain alternative translation starts; 2) both the stop codon of the upstream coding unit and 
the start codon of the downstream coding unit are deleted. It is important to remember that 
many proteins are naturally proteolytically processed and this processing can be upset by 
protein fusion or can interfere with the desired fusion. For example, many proteins are 
secreted into the lumen of the endoplasmic reticulum (ER) with the concomitant cleavage of 
the leader peptide by the signal peptidase. If incorporated within the downstream portion of 
the fusion protein, the signal peptide cleavage sequence can cause undesired fission of the 
fusion protein. Thus, potential problems associated with building of novel fusion proteins 
include protein misfolding, incorrect intracellular localization and unexpected sensitivity to 
a protease attack. In addition, in vivo use of fusion proteins might be impeded by unwanted 
immunogenicity of the newly-created epitopes. 
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Mimicking wild type lentiviruses, splicing signals can be exploited to generate multiple 
mRNAs for different proteins from a single primary transcript (Zhu, Chung et al. 2001). 
However, internal splicing signals reduce the amount of the full size genomic RNA of the 
lentiviral vectors and, therefore, are bound to be detrimental for the vectors’ titres. 
On some occasions several cargo genes within one lentiviral vector can be arranged to be 
driven by their individual promoters. This option is discussed in the following Section 4. 
4. Multiple transcription modules in lentiviral vectors  
The most straightforward way to arrange two transcription cassettes within the lentiviral 
vector is to assemble them in a tandem with the orientation coinciding with the transcription 
direction for the primary genomic RNA (that is, from 5’-LTR to 3’-LTR). Extreme caution is 
recommended in the employment of foreign pA signals in both cassettes, as they can 
interfere with the production of functional genomic RNA of the lentiviral vector. The 
production of functional genomic RNA and transcription from the two gene expression 
cassettes  can all rely on the pA signal within 3’-LTR and a postranscriptional enhancer, 
such as WPRE, positioned immediately upstream from the 3’-LTR. Such tandem 
arrangement of two gene expression units is prone to overriding any regulatory features of 
the downstream promoter by the topmost upstream promoter. Thus, a regulated promoter 
(e.g. a tissue specific promoter) should be positioned in the upstream gene expression unit 
while a constitutive and ubiquitous promoter should be positioned downstream (Gallo, 
Grimaldi et al. 2008; Kita-Matsuo, Barcova et al. 2009). As the lentiviral promoter in the 5’-
LTR can override any regulatory features of the downstream promoters, versions of the 
lentiviral vectors with a deleted 5’-LTR promoter are preferable for tandem assemblies of 
expression cassettes, which include a regulated promoter. There are multiple situations, 
both in gene therapy and in general biomedical research, where an induced transgene 
expression is required. In particular, heat (Vilaboa and Voellmy 2006), light 
(Schoenenberger, Gerosa et al. 2009; Deisseroth 2011) and gas-born acetaldehyde (Weber, 
Rimann et al. 2004) were used for induction of gene expression in mammalian cells 
(Goverdhana, Puntel et al. 2005).  
An alternative solution for the arrangement of two expression cassettes within a lentiviral 
vector genome is an assembly with the divergent orientation of the transcription. The 
advantage of the divergent orientation of the promoters is that it excludes any cross-talk 
between two gene expression units. Therefore, two highly regulated promoters can be 
employed in the same vector. An expression cassette positioned along the transcription of 
the genomic RNA can still use pA signal in 3’-LTR while a counter-genomic-transcription 
unit requires its own pA signal. Care should be taken to use an exclusively unidirectional 
pA signal and not to use a DNA fragment with two opposing pA signals, which can cause 
the disruption of the functional genomic RNA production.  
Lentiviral vectors with tissue-specific promoters can be used for the long-term expression of 
transgenes in gene therapy and also as sensors of cell differentiation, an important task in 
stem-cell-based therapy. There are two principal types of genetic sensors: a “responsive” 
type with a real-time reaction to the cell’s state and a “fate-mapping” type, which, once 
activated, can permanently retain the sensor state during any epigenetic changes happening 
while cells differentiate or react to outside stimuli. As promoters and enhancers are pivotal 
elements of the gene expression control, the ability of lentiviral vectors to accommodate 
several transcription cassettes is an important consideration in the gene vector choice.  
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A flexible way to regulate gene expression is via cistron inversion relative to a promoter 
(Atasoy, Aponte et al. 2008; Sohal, Zhang et al. 2009). Thus, a site-specific recombinase, such 
as Cre-recombinase, can react with the cognate recombination sites within lentiviral vector 
provirus to activate or to block gene expression. Similarly, controlled excision or inversion 
of a transcription terminator can be used as a regulatory contrivance. The expression of 
some genes, e.g. cell suicide genes in cancer gene therapy, requires extra tight control, which 
can be achieved via a parallel or cascade arrangement of two control elements such as an 
inducible promoter and a cistron-inversion system (Sektas, Hasan et al. 2001). Lentiviral 
vectors seem to be particularly suited for the assembly of complex gene expression control 
systems destined for delivery to postmitotic cell populations as their packaging size 
constraints are less prohibitive than the packaging size constraints of competing Adeno-
Associated Virus (AAV) based gene vectors.  
5. Generating non-integrating lentiviral vectors 
One of the current trends in vectorology is for viral vectors to acquire some of the 
advantageous features of non-viral vectors and for non-viral vectors to borrow attractive 
bits of the viral machinery. A clear example of that trend is the rapid coming to the fore of 
non-integrating lentiviral vectors, which are transducing particles still bearing a substantial 
resemblance to lentiviruses and yet deficient in typical for retroviruses random 
chromosomal integration of their proviruses (Nightingale, Hollis et al. 2006; Philippe, Sarkis 
et al. 2006; Yanez-Munoz, Balaggan et al. 2006; Apolonia, Waddington et al. 2007; Philpott 
and Thrasher 2007; Bayer, Kantor et al. 2008; Sarkis, Philippe et al. 2008; Rahim, Wong et al. 
2009). Importantly, non-integrating lentiviral vectors retain the nuclear-penetrating ability, 
the flexibility of virion envelope engineering and capacity to package nucleic acids of the 
therapeutically relevant size that are otherwise characteristic of the lentiviral gene vectors 
(Wanisch and Yanez-Munoz 2009). The benefits of the non-integrative vectors for gene 
therapy arise from the absence of malignancy provoking insertional mutagenesis, which can 
occur because of the disruption of the tumour supressor genes or activation of expression of 
the oncogenes after proviral integration. 
Non-integrating lentiviral vectors are prepared with modified lentiviral packaging systems, 
which employ a modified GagPol polyprotein containing mutations specifically inactivating 
the lentiviral integrase function. If a regular lentiviral vector backbone plasmid is used in the 
packaging procedure, the resultant vector virions can deliver transgenes to the nucleoplasm, 
where the transgenes can stay and be expressed until they are diluted out in cell divisions. 
Therefore, such vectors are suitable either for transient transduction of dividing cells or for 
relatively stable transduction of non-dividing cells, where the lentiviral vector genomes can 
persist. To achieve better maintenance of the transgenes, non-integrating lentiviral vectors 
have to be supplemented with either site-specific integration machinery (Lombardo, 
Genovese et al. 2007; Moldt, Staunstrup et al. 2008) or episomal maintenance apparatus 
(Wong, Argyros et al. 2009; Argyros, Wong et al. 2011).  
Provirus integration can be made harmless by its targeting to a benign locus within the 
target cell genome (Moldt, Staunstrup et al. 2008). The lentiviral integrase itself can be 
engineered into a site-directed recombination enzyme by its fusion with site-specific 
“tethering” domains (Ferris, Wu et al. 2010). Robust and error-free site-specific integration 
into mammalian cells lacking pre-engineered integration sites is, however, difficult to 
achieve. Thus, compact episomal replicons from SV40, polyoma, papilloma viruses or 
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EBNA1-Rep1 DNA segment of Epstein-Barr virus (EBV) can be used to support 
maintenance of non-integrating lentiviral vectors in the nucleoplasm of dividing cells. Viral 
replicons are often completely adequate for research use of gene vectors, however they are 
rarely acceptable for therapeutic applications. Indeed, expression of the large SV40 T-
antigen and, hence, malignant transformation of the recipient host cells is required for SV40-
origin-based replication. EBNA1 expression does not result in a typical malignant 
transformation but can still tilt the cells towards the undesired immortalisation (Humme, 
Reisbach et al. 2003). Alternative benign episomal replicons are being sought; 
encouragingly,  the scaffold/matrix attachment region (S/MAR) from the human β-
interferon gene was reported to support episomal replication (Wong, Argyros et al. 2011).  
6. How to enhance the transduction of cells with lentiviral vectors 
The titre of lentiviral vector particles in the cell culture supernatant hardly ever exceeds 
1x108 TU/ml and, depending on a particular lentiviral vector backbone, is often much 
lower. Therefore, the use of concentrated lentiviral vector preparations is a popular, even 
though relatively involved, approach to achieve high efficiency of transduction with small 
volumes of the applied viral vector suspension. In addition to increased titres, concentrated 
lentiviral vector preparations benefit from concomitant purification of viral vector particles 
from transduction inhibitors, which are commonly present in the cell culture supernatants. 
Ultracentrifugation is a traditional method to concentrate lentiviral vector virions, however 
it is often accompanied by the loss of a substantial fraction of the active lentiviral vector 
particles. The particles are, in part, inactivated because of the contact between the vector 
pellet and air. To make the pellet more compact, ultracentrifugation is performed in swing-
out bucket rotors and conical-bottom tubes supplemented with appropriate adaptors.  
Centrifugal force can also cause deterioration of sedimenting vector particles, so a bottom 
layer of dense sucrose solution is recommended as a “cushion” for better survival of the 
vector virions. The cushion is also important because a considerable portion of the lentiviral 
vector preparation can be lost due to incomplete wash-off of the viral vector pellet from the 
tube or its poor re-suspension.  VSV-G pseudotyped lentiviral vectors have relatively short 
half-life of 8-9 hrs at 37 oC and are better stored at -80 oC. 
Similarly to other virions, lentiviral vector particles can be precipitated using “molecular 
crowding” agents such as polyethylene glycol (PEG), which can soak up water molecules 
and create micro-pockets with an extra-high virion concentration. Thus, precipitation of 
virions can be achieved by a proprietary reagent “Lenti-XTM concentrator” supplied by 
Clontech-Takara. Precipitated lentiviral vector particles can be pelleted by low-speed 
centrifugation and re-suspended in a smaller volume. However, some non-lentiviral 
material from cell culture supernatants tends to co-precipitate with virions complicating the 
re-suspension step. Therefore, additional viral vector purification is required, which is often 
performed by ion exchange chromatography. Lentiviral vector particles are eluted from the 
ion exchange column in a high salt solution, which can be toxic to cells. Therefore, the 
medium for lentiviral vector particles should be exchanged to the desired one using dialysis, 
gel filtration or ultrafiltration. Ultrafiltration also provides a means for additional 
concentration of the viral vector.  
A completely different strategy for the lentiviral vector concentration is to bind the vector 
particles to a coated plastic surface, which can then be used as a substrate for the cells to be 
infected. A recombinant derivative of human fibronectin called RetroNectinTM, which was 
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originally used for surface immobilisation of amphotropic retroviral vectors, can be used to 
trammel VSV-G pseudotyped lentiviral vectors on a plastic surface (Clontech-Takara). 
Lentiviral vector virions can also be concentrated, including directly at the recipient cell 
surfaces, after conjugation to paramagnetic particles and attraction by magnet.  
Receptors for VSV-G protein are ubiquitous, but still poorly defined. Various types of cells 
are transduced by VSV-G-pseudotyped lentiviral vectors with different efficiency. A higher 
efficiency of transduction can often be achieved by a better match of the recipient cells’ type 
and the type of the envelope protein used to pseudotype lentiviral vector particles. 
Lentiviral transduction is normally dramatically enhanced by polycations, such as 
hexadimethrine bromide (Polybrene), presumably because they modify the electrostatic 
interaction between the cells and the vector particles. The polycations’ transduction 
enhancer activity is highly cell specific. Alternative polycations, such as positively charged 
lipid dioctadecylamidoglycylspermine (DOGS), can be more effective than Polybrene for 
specific cell populations (Tolmachov, Ma et al. 2006). Transduction efficiency can be further 
increased by a very unusual and poorly understood method called “spinfection”. The 
recipient cells are overlaid by a viral vector suspension and centrifuged at low speed for 45 
min or more. In most circumstances, such a centrifugation step results in a distinct increase 
in the transduction efficiency, perhaps because of the changes in the trajectories of vector-
laden endosomal vesicles due to the centrifugal force. 
Lentiviral vectors are able to transduce non-dividing cells. However, higher efficiencies of 
transduction are achieved with dividing cells, indicating that the nuclear envelope still 
constitutes a difficult barrier to negotiate for the entering lentiviral vector particles. 
Therefore, growth factors that stimulate cell division can be applied to increase the 
efficiency of the lentiviral transduction.  
In addition to the measurement of the transduction activity, a lentiviral vector titre can be 
estimated using physical methods such as electron microscopy or enzyme-linked 
immunosorbent assay (ELISA) for capsid protein (such as “p24-antigen” of HIV-1). The titre 
of viral vector particles can be inferred from the concentration of genomic RNA determined 
by quantitative (real time) PCR. As the proportion of defective viral vector particles can vary 
depending on the procedures used to isolate and to concentrate the vector, such projections 
should rely on individually built calibration plots relating the physical titre and the 
transduction-based titre for a specific set of the viral vector production protocols. 
7. Conclusion 
Lentiviral gene vectors are generated by the packaging of the RNA transcribed in 
mammalian cells from vector backbone plasmids propagated in bacteria. Such plasmids 
contain bacterial and eukaryotic sets of elements. The bacterial set is comprised of a plasmid 
origin of replication, a bacterial selection marker, an optional partition region for stable 
maintenance in bacteria and plasmid DNA manipulation prop-ups like multiple cloning 
sites and site-specific recombination sites. The eukaryotic set consists of the lentiviral cis-
acting determinants for nuclear export of vector genomes, their packaging, entry into the 
target nuclei and chromosomal integration, plus a cargo gene or multiple cargo genes with 
their regulatory elements, an optional marker gene and the elements required for stable 
maintenance of transgenes in human cells. The bacterial set of elements is lost after vector 
genome RNA is produced and packaged into lentiviral transducing particles. Different 
cargo genes can be delivered with lentiviral vectors including genes for proteins, shRNA 
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and miRNA. Currently lentiviral vectors are packaged in mammalian cells only (Lesch, 
Laitinen et al. 2011). The development of straightforward lentiviral vector production 
systems in easily cultured insect cells and yeast would be desirable (Tolmachov 2006).  
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